Macrophage immunometabolic programming in pulmonary arterial hypertension: prioritizing TET2 and METTL3/m⁶A
Abstract
Pulmonary arterial hypertension (PAH) is sustained by pulmonary vascular remodeling and right ventricular (RV) maladaptation that often remain incompletely reversible despite contemporary pathway-directed therapy. A central mechanistic question is how macrophage states that promote remodeling are maintained. This focused narrative review examines three potentially coexisting explanations: continued conditioning by the pathological niche, selective recruitment of monocyte subsets with pre-existing inflammatory signatures, and cell-intrinsic regulatory states that persist after stimulus withdrawal. Single-cell and spatial studies identify lesion-, subset- and stage-dependent macrophage states, but cannot alone distinguish these explanations. Metabolic regulation of chromatin and RNA provides candidate links between local cues and sustained function. We compare TET2-dependent DNA regulation and METTL3/m6A-dependent RNA fate as complementary routes through which metabolic cues may influence inflammatory restraint and effector output. Human associations and hematopoietic or myeloid perturbation studies support their investigation, but do not establish durable programming in human lesional macrophages. We therefore distinguish ongoing activation from persistent programming and trained immunity, evaluate pulmonary and RV evidence separately, and define the validation requirements for testing whether disruption of macrophage-state maintenance can reverse established disease.
Related
- TREM2 Orchestrates Myeloid Cell Programming and Immune Dysregulation in Pulmonary Hypertension
- Lactylation modification: a new bridge connecting macrophage metabolism and pulmonary hypertension.
- Integrative single-cell and bulk transcriptomic analysis identifies monocyte/macrophage senescence-associated candidate genes in pulmonary arterial hypertension
- Macrophage states and immunometabolic adaptation in peritoneal metastases from colorectal cancer
- Nanotherapeutic macrophage reprogramming through immunometabolic and microbial modulation for sepsis treatment.
BibTeX
@article{meng2026macrophage,
title = {{Macrophage immunometabolic programming in pulmonary arterial hypertension: prioritizing TET2 and METTL3/m⁶A}},
author = {Hui Meng and Juan Liao and Li Peng and Yan Deng},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1904863},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1904863},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Macrophage immunometabolic programming in pulmonary arterial hypertension: prioritizing TET2 and METTL3/m⁶A
AU - Hui Meng
AU - Juan Liao
AU - Li Peng
AU - Yan Deng
PY - 2026
DA - 2026/11/06
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1904863
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1904863
AB - Pulmonary arterial hypertension (PAH) is sustained by pulmonary vascular remodeling and right ventricular (RV) maladaptation that often remain incompletely reversible despite contemporary pathway-directed therapy. A central mechanistic question is how macrophage states that promote remodeling are maintained. This focused narrative review examines three potentially coexisting explanations: continued conditioning by the pathological niche, selective recruitment of monocyte subsets with pre-existing inflammatory signatures, and cell-intrinsic regulatory states that persist after stimulus withdrawal. Single-cell and spatial studies identify lesion-, subset- and stage-dependent macrophage states, but cannot alone distinguish these explanations. Metabolic regulation of chromatin and RNA provides candidate links between local cues and sustained function. We compare TET2-dependent DNA regulation and METTL3/m6A-dependent RNA fate as complementary routes through which metabolic cues may influence inflammatory restraint and effector output. Human associations and hematopoietic or myeloid perturbation studies support their investigation, but do not establish durable programming in human lesional macrophages. We therefore distinguish ongoing activation from persistent programming and trained immunity, evaluate pulmonary and RV evidence separately, and define the validation requirements for testing whether disruption of macrophage-state maintenance can reverse established disease.
SN - 1664-3224
ER -